Tertatolol does not affect biochemical markers of atherosclerosis in normo- and hyperlipidemic hypertensive patients.
The effects of the beta-blocker tertatolol on plasma lipids and lipoproteins were studied in two groups of 10 normolipidemic (group I) and 10 hyperlipidemic (group II) hypertensive patients, for a period of 3 months. The efficacy of tertatolol was confirmed by a reduction in heart rate (HR), and in systolic (SBP) and diastolic (DBP) blood pressure, in the supine position and after 1 min in the upright position. Triglyceride (TG) levels were increased by treatment in both groups (+20% and +22%, respectively; p less than 0.05), as were VLDL levels (+16% and +24%, respectively) although the rise in the latter was not significant. There were no significant differences in levels of HDL cholesterol (HDL-C), HDL, or apoproteins A and A1 (APO A, APO A1). Total cholesterol (TC) levels were increased by treatment in group I (+10%; p = 0.050) and decreased in group II (-9%, not significant), LDL-C being the principal fraction involved in these changes. There were no significant differences in levels of APO B. The ratio between TC and HDL-C levels remained unchanged. Given the current state of our knowledge concerning lipid markers for atherosclerosis, these results indicate that chronic administration of tertatolol may be considered devoid of 'atherogenic' effects.